O	0	1	A
O	2	7	Phase
O	8	11	III
O	12	17	Study
O	18	20	of
B-intervention	21	32	Balugrastim
O	33	39	Versus
B-control	40	53	Pegfilgrastim
O	54	56	in
O	57	63	Breast
O	64	70	Cancer
O	71	79	Patients
O	80	89	Receiving
O	90	102	Chemotherapy
O	103	107	With
O	108	119	Doxorubicin
O	120	123	and
O	124	133	Docetaxel
O	133	134	.

O	135	139	This
O	140	145	study
O	146	151	aimed
O	152	154	to
O	155	163	evaluate
O	164	167	the
O	168	176	efficacy
O	177	180	and
O	181	187	safety
O	188	190	of
O	191	195	once
O	195	196	-
O	196	199	per
O	199	200	-
O	200	205	cycle
O	206	217	balugrastim
O	218	224	versus
O	225	238	pegfilgrastim
O	239	242	for
O	243	253	neutrophil
O	254	261	support
O	262	264	in
O	265	271	breast
O	272	278	cancer
O	279	287	patients
O	288	297	receiving
O	298	314	myelosuppressive
O	315	327	chemotherapy
O	327	328	.

B-eligibility	329	335	Breast
I-eligibility	336	342	cancer
I-eligibility	343	351	patients
O	352	353	(
O	353	354	n
O	355	356	=
B-total-participants	357	360	256
O	360	361	)
O	362	366	were
O	367	377	randomized
O	378	380	to
O	381	383	40
O	384	386	or
O	387	389	50
O	390	392	mg
O	393	395	of
O	396	408	subcutaneous
O	409	420	balugrastim
O	421	423	or
O	424	425	6
O	426	428	mg
O	429	431	of
O	432	445	pegfilgrastim
O	446	447	≈
O	447	449	24
O	450	455	hours
O	456	461	after
O	462	474	chemotherapy
O	475	476	(
O	476	478	60
O	479	481	mg
O	481	482	/
O	482	483	m
O	483	484	(
O	484	485	2
O	485	486	)
O	487	498	doxorubicin
O	499	502	and
O	503	505	75
O	506	508	mg
O	508	509	/
O	509	510	m
O	510	511	(
O	511	512	2
O	512	513	)
O	514	523	docetaxel
O	523	524	,
O	525	530	every
O	531	533	21
O	534	538	days
O	539	542	for
O	543	545	up
O	546	548	to
O	549	550	4
O	551	557	cycles
O	557	558	)
O	558	559	.

O	560	563	The
O	564	571	primary
O	572	580	efficacy
O	581	590	parameter
O	591	594	was
O	595	598	the
B-outcome-Measure	599	607	duration
I-outcome-Measure	608	610	of
I-outcome-Measure	611	617	severe
I-outcome-Measure	618	629	neutropenia
I-outcome-Measure	630	631	(
I-outcome-Measure	631	634	DSN
I-outcome-Measure	634	635	)
O	636	638	in
O	639	644	cycle
O	645	646	1
O	646	647	.

O	648	657	Secondary
O	658	668	parameters
O	669	677	included
B-outcome-Measure	678	681	DSN
I-outcome-Measure	682	683	(
I-outcome-Measure	683	689	cycles
I-outcome-Measure	690	691	2
I-outcome-Measure	691	692	-
I-outcome-Measure	692	693	4
I-outcome-Measure	693	694	)
O	694	695	,
B-outcome-Measure	696	704	absolute
I-outcome-Measure	705	715	neutrophil
I-outcome-Measure	716	721	count
I-outcome-Measure	722	723	(
I-outcome-Measure	723	726	ANC
I-outcome-Measure	726	727	)
I-outcome-Measure	728	733	nadir
O	733	734	,
B-outcome-Measure	735	742	febrile
I-outcome-Measure	743	754	neutropenia
I-outcome-Measure	755	760	rates
O	760	761	,
O	762	765	and
B-outcome-Measure	766	770	time
I-outcome-Measure	771	773	to
I-outcome-Measure	774	777	ANC
I-outcome-Measure	778	786	recovery
I-outcome-Measure	787	788	(
I-outcome-Measure	788	794	cycles
I-outcome-Measure	795	796	1
I-outcome-Measure	796	797	-
I-outcome-Measure	797	798	4
I-outcome-Measure	798	799	)
O	799	800	.

O	801	807	Safety
O	807	808	,
O	809	825	pharmacokinetics
O	825	826	,
O	827	830	and
O	831	845	immunogenicity
O	846	850	were
O	851	859	assessed
O	859	860	.

B-outcome	861	865	Mean
I-outcome	866	871	cycle
I-outcome	872	873	1
I-outcome	874	877	DSN
O	878	881	was
B-iv-cont-mean	882	883	1
I-iv-cont-mean	883	884	.
I-iv-cont-mean	884	885	0
I-iv-cont-mean	886	889	day
O	890	894	with
O	895	897	40
O	898	900	mg
O	901	903	of
O	904	915	balugrastim
O	915	916	,
B-iv-cont-mean	917	918	1
I-iv-cont-mean	918	919	.
I-iv-cont-mean	919	920	3
O	921	925	with
O	926	928	50
O	929	931	mg
O	932	934	of
O	935	946	balugrastim
O	946	947	,
O	948	951	and
B-cv-cont-mean	952	953	1
I-cv-cont-mean	953	954	.
I-cv-cont-mean	954	955	2
O	956	960	with
O	961	974	pegfilgrastim
O	975	976	(
O	976	981	upper
O	982	987	limit
O	988	990	of
O	991	993	95
O	993	994	%
O	995	1005	confidence
O	1006	1015	intervals
O	1016	1019	for
O	1020	1027	between
O	1027	1028	-
O	1028	1033	group
O	1034	1037	DSN
O	1038	1049	differences
O	1050	1053	was
O	1054	1055	<
O	1055	1056	1
O	1056	1057	.
O	1057	1058	0
O	1059	1062	day
O	1063	1066	for
O	1067	1071	both
O	1072	1083	balugrastim
O	1084	1089	doses
O	1090	1096	versus
O	1097	1110	pegfilgrastim
O	1110	1111	)
O	1111	1112	.

O	1113	1120	Between
O	1120	1121	-
O	1121	1126	group
O	1127	1135	efficacy
O	1136	1146	parameters
O	1147	1151	were
O	1152	1162	comparable
O	1163	1169	except
O	1170	1173	for
B-outcome	1174	1178	time
I-outcome	1179	1181	to
I-outcome	1182	1185	ANC
I-outcome	1186	1194	recovery
I-outcome	1195	1197	in
I-outcome	1198	1203	cycle
I-outcome	1204	1205	1
O	1206	1207	(
O	1207	1209	40
O	1210	1212	mg
O	1213	1215	of
O	1216	1227	balugrastim
O	1227	1228	,
B-iv-cont-mean	1229	1230	2
I-iv-cont-mean	1230	1231	.
I-iv-cont-mean	1231	1232	0
I-iv-cont-mean	1233	1237	days
O	1237	1238	;
O	1239	1241	50
O	1242	1244	mg
O	1245	1247	of
O	1248	1259	balugrastim
O	1259	1260	,
B-iv-cont-mean	1261	1262	2
I-iv-cont-mean	1262	1263	.
I-iv-cont-mean	1263	1264	1
O	1264	1265	;
O	1266	1279	pegfilgrastim
O	1279	1280	,
B-cv-cont-mean	1281	1282	2
I-cv-cont-mean	1282	1283	.
I-cv-cont-mean	1283	1284	6
O	1284	1285	)
O	1285	1286	.

B-outcome	1287	1293	Median
I-outcome	1294	1302	terminal
I-outcome	1303	1314	elimination
O	1315	1319	half
O	1319	1320	-
O	1320	1324	life
O	1325	1328	was
O	1329	1330	≈
B-iv-cont-median	1330	1332	37
I-iv-cont-median	1333	1338	hours
O	1339	1342	for
O	1343	1345	40
O	1346	1348	mg
O	1349	1351	of
O	1352	1363	balugrastim
O	1363	1364	,
O	1365	1366	≈
B-iv-cont-median	1366	1368	36
O	1369	1372	for
O	1373	1375	50
O	1376	1378	mg
O	1379	1381	of
O	1382	1393	balugrastim
O	1393	1394	,
O	1395	1398	and
O	1399	1400	≈
B-cv-cont-median	1400	1402	45
O	1403	1406	for
O	1407	1420	pegfilgrastim
O	1420	1421	.

B-outcome	1422	1430	Antibody
I-outcome	1431	1439	response
O	1440	1442	to
O	1443	1454	balugrastim
O	1455	1458	was
O	1459	1462	low
O	1463	1466	and
O	1467	1476	transient
O	1476	1477	,
O	1478	1482	with
O	1483	1485	no
O	1486	1498	neutralizing
O	1499	1505	effect
O	1505	1506	.

O	1507	1511	Once
O	1511	1512	-
O	1512	1515	per
O	1515	1516	-
O	1516	1521	cycle
O	1522	1533	balugrastim
O	1534	1536	is
O	1537	1540	not
O	1541	1549	inferior
O	1550	1552	to
O	1553	1566	pegfilgrastim
O	1567	1569	in
B-outcome	1570	1578	reducing
I-outcome	1579	1584	cycle
I-outcome	1585	1586	1
I-outcome	1587	1590	DSN
O	1591	1593	in
O	1594	1600	breast
O	1601	1607	cancer
O	1608	1616	patients
O	1617	1626	receiving
O	1627	1639	chemotherapy
O	1639	1640	;
O	1641	1645	both
O	1646	1651	drugs
O	1652	1656	have
O	1657	1667	comparable
O	1668	1674	safety
O	1675	1683	profiles
O	1683	1684	.

O	1685	1689	This
O	1690	1695	paper
O	1696	1704	provides
O	1705	1713	efficacy
O	1714	1717	and
O	1718	1724	safety
O	1725	1729	data
O	1730	1733	for
O	1734	1735	a
O	1736	1739	new
O	1739	1740	,
O	1741	1745	once
O	1745	1746	-
O	1746	1749	per
O	1749	1750	-
O	1750	1755	cycle
O	1756	1767	granulocyte
O	1768	1774	colony
O	1774	1775	-
O	1775	1786	stimulating
O	1787	1793	factor
O	1793	1794	,
O	1795	1806	balugrastim
O	1806	1807	,
O	1808	1811	for
O	1812	1815	the
O	1816	1826	prevention
O	1827	1829	of
O	1830	1842	chemotherapy
O	1842	1843	-
O	1843	1850	induced
O	1851	1862	neutropenia
O	1863	1865	in
O	1866	1874	patients
O	1875	1879	with
O	1880	1886	breast
O	1887	1893	cancer
O	1894	1903	receiving
O	1904	1920	myelosuppressive
O	1921	1933	chemotherapy
O	1933	1934	.

O	1935	1937	In
O	1938	1942	this
O	1943	1948	phase
O	1949	1952	III
O	1953	1958	trial
O	1958	1959	,
O	1960	1971	balugrastim
O	1972	1975	was
O	1976	1981	shown
O	1982	1984	to
O	1985	1987	be
O	1988	1991	not
O	1992	2000	inferior
O	2001	2003	to
O	2004	2017	pegfilgrastim
O	2018	2020	in
O	2021	2024	the
O	2025	2033	duration
O	2034	2036	of
O	2037	2043	severe
O	2044	2055	neutropenia
O	2056	2058	in
O	2059	2064	cycle
O	2065	2066	1
O	2067	2069	of
O	2070	2081	doxorubicin
O	2081	2082	/
O	2082	2091	docetaxel
O	2092	2104	chemotherapy
O	2104	2105	,
O	2106	2109	and
O	2110	2113	the
O	2114	2120	safety
O	2121	2129	profiles
O	2130	2132	of
O	2133	2136	the
O	2137	2140	two
O	2141	2147	agents
O	2148	2152	were
O	2153	2160	similar
O	2160	2161	.

O	2162	2166	Once
O	2166	2167	-
O	2167	2170	per
O	2170	2171	-
O	2171	2176	cycle
O	2177	2188	balugrastim
O	2189	2191	is
O	2192	2193	a
O	2194	2198	safe
O	2199	2202	and
O	2203	2212	effective
O	2213	2224	alternative
O	2225	2227	to
O	2228	2241	pegfilgrastim
O	2242	2245	for
O	2246	2259	hematopoietic
O	2260	2267	support
O	2268	2270	in
O	2271	2279	patients
O	2280	2284	with
O	2285	2291	breast
O	2292	2298	cancer
O	2299	2308	receiving
O	2309	2325	myelosuppressive
O	2326	2338	chemotherapy
O	2339	2349	associated
O	2350	2354	with
O	2355	2356	a
O	2357	2364	greater
O	2365	2369	than
O	2370	2372	20
O	2372	2373	%
O	2374	2378	risk
O	2379	2381	of
O	2382	2392	developing
O	2393	2400	febrile
O	2401	2412	neutropenia
O	2412	2413	.
